


Reduced Coinsurance for Certain Part B Rebatable Drugs under the Medicare Prescription Drug Inflation Rebate Program



Applicable October 1 – December 31, 2023

President Biden’s historic Inflation Reduction Act requires drug companies to pay rebates to Medicare when prescription drug prices increase faster than the rate of inflation for certain drugs furnished to people with Medicare. This new inflation rebate applies to Medicare Part B rebatable drugs, which are single source drugs and biological products, including certain biosimilar biological products, beginning January 1, 2023.

The federal government intends to invoice drug manufacturers for 2023 and 2024 Part B inflation rebates no later than fall 2025. The rebates will be deposited into the Medicare Trust Fund. In addition, beginning April 1, 2023, people with Medicare may see lower out-of-pocket costs for certain Part B drugs and biologicals with prices that have increased faster than the rate of inflation. For these drugs and biologicals, the beneficiary coinsurance will be 20% of the inflation-adjusted payment amount, which will be less than what the beneficiary would pay in coinsurance otherwise.

CMS posts payment information each quarter for separately payable Part B drugs, including the Part B rebatable drugs subject to the coinsurance adjustments, in the Medicare Part B Quarterly Sales Pricing (ASP) files, which are publicly available on CMS.gov. The October 2023 ASP public files will also include the coinsurance adjustments for certain Part B rebatable drugs as required by the Inflation Reduction Act. The Part B drugs impacted by a coinsurance adjustment may change quarterly.

For the time period of October 1 – December 31, 2023 34 Part B rebatable drugs have an adjusted coinsurance rate based on the inflation-adjusted payment amount. People with Traditional Medicare and Medicare Advantage who use these drugs may, depending on other health coverage they may have, pay a reduced amount for their coinsurance during this specific quarter. For the quarter, October 1 – December 31, people with Medicare may experience coinsurance amounts that are lower than what they would have paid before the new law passed by as much as \$1-618 per average dose.

CMS’ normal procedure is to release the ASP public files several weeks before the quarter they will go into effect so the public can review and notify CMS of any potential discrepancies. From time to time, ASP public files need to be corrected or updated, generally referred to as a restatement, based on feedback received after the files are published. If CMS receives feedback that necessitates updates to this list of drugs with adjusted coinsurance amounts, CMS will update the list. The October 1 – December 31, 2023 files may be subject to updates either before the start of the quarter or after in the event updated data becomes available.

Below is the list of 34 drugs with adjusted coinsurance amounts for the quarter October 1 – December 31, 2023. Learn more about the **Medicare Prescription Drug Inflation Rebate Program** including a fact sheet on the Part B rebatable drug coinsurance reduction.

HCPCS	Drug name	Inflation-Adjusted Coinsurance Percentage (Normally 20.000%)
J9042	ADCETRIS	19.754%
J3246	AGGRASTAT	19.698%
J8655	AKYNZEO	17.996%
J7504	ATGAM	16.834%
J0558	BICILLIN CR	17.741%
J0561	BICILLIN L-A	17.484%
J9039	BLINCYTO	19.517%
J2850	CHIRHOSTIM	19.328%
J1833	CRESEMBA	19.997%
J0584	CRYSVITA	19.744%
J1645	FRAGMIN	13.158%
J0135	HUMIRA	19.997%
J1670	HYPERTET	19.207%
J9325	IMLYGIC	19.772%
J9198	INFUGEM	19.669%
J2820	LEUKINE	19.711%
J1950	LUPRON DEPOT-PED	19.895%
J2265	MINOCIN	18.828%
J9268	NIPENT	19.562%
J2796	NPLATE	19.935%
J9266	ONCASPAR	19.382%
J9177	PADCEV	19.229%
J1640	PANHEMATIN	19.536%
J9314	PEMETREXED	13.634%
J9318	ROMIDEPSIN	19.509%
J9061	RYBREVAANT	19.908%

HCPCS	Drug name	Inflation-Adjusted Coinsurance Percentage (Normally 20.000%)
J2502	SIGNIFOR LAR	17.881%
C9482	SOTALOL	19.729%
J2860	SYLVANT	18.984%
J9262	SYNRIBO	19.378%
J2186	VABOMERE	19.554%
J9303	VECTIBIX	19.921%
J0775	XIAFLEX	18.626%
J0291	ZEMDRI	19.739%